Patents by Inventor Bruce A. Yankner
Bruce A. Yankner has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20080274456Abstract: The invention relates to gene regulation in ageing, and age-related cognitive decline. The invention, in particular relates to methods for screening a subject for a propensity to develop diseases associated with oxidative stress, and for age-related conditions, by examining the up-regulation and/or down-regulation of at least one gene associated within the central nervous system.Type: ApplicationFiled: June 9, 2005Publication date: November 6, 2008Inventors: Bruce Yankner, Tao Lu
-
Publication number: 20060025469Abstract: Blood cholesterol levels are correlated with production of amyloid ? protein (A?), and are predictors of populations at risk of developing AD. Methods for lowering blood cholesterol levels can be used to decrease production of A?, thereby decreasing the risk of developing AD. The same methods and compositions can also be used for treating individuals diagnosed with AD. Methods include administration of compounds which increase uptake of cholesterol by the liver, such as the administration of HMG CoA reductase inhibitors, administration of compounds which block endogenous cholesterol production, such as administration of HMG CoA reductase inhibitors, administration of compositions which prevent uptake of dietary cholesterol, and administration of combinations of any of these which are effective to lower blood cholesterol levels. Methods have also been developed to predict populations at risk, based on the role of cholesterol in production of A?.Type: ApplicationFiled: September 22, 2005Publication date: February 2, 2006Inventors: Bruce Yankner, Philip Nadeau
-
Publication number: 20020183379Abstract: Blood cholesterol levels are correlated with production of amyloid &bgr; protein (A&bgr;), and are predictors of populations at risk of developing AD. Methods for lowering blood cholesterol levels can be used to decrease production of A&bgr;, thereby decreasing the risk of developing AD. The same methods and compositions can also be used for treating individuals diagnosed with AD. Methods include administration of compounds which increase uptake of cholesterol by the liver, such as the administration of HMG CoA reductase inhibitors, administration of compounds which block endogenous cholesterol production, such as administration of HMG CoA reductase inhibitors, administration of compositions which prevent uptake of dietary cholesterol, and administration of combinations of any of these which are effective to lower blood cholesterol levels, Methods have also been developed to predict populations at risk, based on the role of cholesterol in production of A&bgr;.Type: ApplicationFiled: July 14, 2002Publication date: December 5, 2002Applicant: Children's Medical Center CorporationInventors: Bruce A. Yankner, Philip Nadeau
-
Publication number: 20020120003Abstract: Blood cholesterol levels are correlated with production of amyloid &bgr; protein (A&bgr;), and are predictors of populations at risk of developing AD. Methods for lowering blood cholesterol levels can be used to decrease production of A&bgr;, thereby decreasing the risk of developing AD. The same methods and compositions can also be used for treating individuals diagnosed with AD. Methods include administration of compounds which increase uptake of cholesterol by the liver, such as the administration of HMG CoA reductase inhibitors, administration of compounds which block endogenous cholesterol production, such as administration of HMG CoA reductase inhibitors, administration of compositions which prevent uptake of dietary cholesterol, and administration of combinations of any of these which are effective to lower blood cholesterol levels. Methods have also been developed to predict populations at risk, based on the role of cholesterol in production of A&bgr;.Type: ApplicationFiled: February 28, 2002Publication date: August 29, 2002Applicant: Children's Medical Center CorporationInventors: Bruce A. Yankner, Philip Nadeau
-
Patent number: 6440387Abstract: Blood cholesterol levels are correlated with production of amyloid &bgr; protein (A&bgr;), and are predictors of populations at risk of developing AD. Methods for lowering blood cholesterol levels can be used to decrease production of A&bgr;, thereby decreasing the risk of developing AD. The same methods and compositions can also be used for treating individuals diagnosed with AD. Methods include administration of compounds which increase uptake of cholesterol by the liver, such as the administration of HMG CoA reductase inhibitors, administration of compounds which block endogenous cholesterol production, such as administration of HMG CoA reductase inhibitors, administration of compositions which prevent uptake of dietary cholesterol, and administration of combinations of any of these which are effective to lower blood cholesterol levels. Methods have also been developed to predict populations at risk, based on the role of cholesterol in production of A&bgr;.Type: GrantFiled: January 28, 1999Date of Patent: August 27, 2002Assignee: Children's Medical Center CorporationInventors: Bruce A. Yankner, Philip Nadeau
-
Publication number: 20020081263Abstract: Blood cholesterol levels are correlated with production of amyloid &bgr; protein (A&bgr;), and are predictors of populations at risk of developing AD. Methods for lowering blood cholesterol levels can be used to decrease production of A&bgr;, thereby decreasing the risk of developing AD. The same methods and compositions can also be used for treating individuals diagnosed with AD. Methods include administration of compounds which increase uptake of cholesterol by the liver, such as the administration of HMG CoA reductase inhibitors, administration of compounds which block endogenous cholesterol production, such as administration of HMG CoA reductase inhibitors, administration of compositions which prevent uptake of dietary cholesterol, and administration of combinations of any of these which are effective to lower blood cholesterol levels. Methods have also been developed to predict populations at risk, based on the role of cholesterol in production of A&bgr;.Type: ApplicationFiled: January 28, 1999Publication date: June 27, 2002Inventors: BRUCE A. YANKNER, PHILIP NADEAU
-
Patent number: 6080778Abstract: Blood cholesterol levels are correlated with production of amyloid .beta. protein (A.beta.), and are predictors of populations at risk of developing AD. Methods for lowering blood cholesterol levels can be used to decrease production of A.beta., thereby decreasing the risk of developing AD. The same methods and compositions can also be used for treating individuals diagnosed with AD. Methods include administration of compounds which increase uptake of cholesterol by the liver, such as the administration of HMG CoA reductase inhibitors, administration of compounds which block endogenous cholesterol production, such as administration of HMG CoA reductase inhibitors, administration of compositions which prevent uptake of dietary cholesterol, and administration of combinations of any of these which are effective to lower blood cholesterol levels. Methods have also been developed to predict populations at risk, based on the role of cholesterol in production of A.beta..Type: GrantFiled: March 23, 1998Date of Patent: June 27, 2000Assignee: Children's Medical Center CorporationInventors: Bruce A. Yankner, Philip Nadeau
-
Patent number: 5876948Abstract: Method for treatment of a disease in a patient characterized by accumulation of .beta.-amyloid. The method includes identifying a patient potentially suffering from such a disease and contacting a neuron of the patient with a therapeutically effective amount of a tachykinin agonist. Methods for screening for compounds useful for treating such a disease are also disclosed.Type: GrantFiled: July 29, 1991Date of Patent: March 2, 1999Assignee: The Children's Medical Center CorporationInventor: Bruce A. Yankner
-
Patent number: 5137873Abstract: Method for treatment of a disease in a patient characterized by accumulation of .beta.-amyloid. The method includes identifying a patient potentially suffering from such a disease and contacting a neuron of the patient with a therapeutically effective amount of a tachykinin agonist such as substance P. Methods for screening for compounds useful for treating such a disease are also disclosed.Type: GrantFiled: July 27, 1990Date of Patent: August 11, 1992Assignee: The Children's Medical Center CorporationInventor: Bruce A. Yankner